Opendata, web and dolomites

StableVax

Commercialisation of a world changing invention for the stabilisation and delivery of vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StableVax project word cloud

Explore the words cloud of the StableVax project. It provides you a very rough idea of what is the project "StableVax" about.

100    optimum    designed    cold    liquid    stablepharma    officer    human    exposed    lose    finely    dr    biological    stable    stored    fighting    keep    vaccination    error    special    unnecessary    pioneer    inserted    tool    revolutionary    storage    sensitive    syringe    invitation    disable    assist    removal    roser    annually    factory    variety    containing    globe    rendered    buffer    material    refrigerated    50    indispensable    wastage    monitored    sub    eliminate    lives    ltd    stabilise    dissolved    millions    effectiveness    2012    disease    customer    transported    saved    dry    tens    compressible    global    january    chain    temperatures    organisation    completely    bruce    failings    introducing    scientific    chief    vision    geneva    fails    world    guidance    left    stabilisation    saving    scientist    standard    accreditation    innovative    vaccine    useless    chairman    patented    invention    auto    closely    distinguished    turn    units    divided    company    frequently    incorporated    constant    relies    vaccines    series    commercialise    simply    absorbed    health    temperature    cso    porous   

Project "StableVax" data sheet

The following table provides information about the project.

Coordinator
STABLEPHARMA LIMITED 

Organization address
address: 1 QUEEN SQUARE
city: BATH
postcode: BA1 2HA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://stablepharma.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STABLEPHARMA LIMITED UK (BATH) coordinator 50˙000.00

Map

 Project objective

Vaccination is an indispensable tool in fighting disease, annually saving up tens of millions of lives saved across the globe. Vaccines are biological products that are sensitive to temperature change and can lose their effectiveness if exposed to sub optimum temperatures. The delivery of vaccines from the factory to the customer currently relies on a closely monitored cold chain process containing a series of refrigerated storage units, designed to keep the vaccine at a constant temperature. The system frequently fails for a variety of reasons, some technical and some simply due to human error. Currently 50% of the world’s vaccines are rendered useless due to the failings of the present refrigerated ‘cold chain’ delivery systems Stablepharma has a vision to eliminate the global cold chain and unnecessary vaccine wastage by introducing an innovative method to stabilise vaccines allowing them to be transported and stored at a wide-range of temperatures. Our technology involves the ~100% removal of liquid from vaccine dissolved in a special buffer, so that it is left in a completely stable and finely divided dry state absorbed into a, compressible, porous material that is in turn inserted into a standard auto-disable syringe. The process and invention was introduced to the WHO (World Health Organisation, Geneva) by invitation in 2012 and they have been able to assist the company with guidance in the development and accreditation process. Stablepharma Ltd was incorporated in January 2012 to commercialise a revolutionary vaccine stabilisation invention and process developed and patented by our Chief Scientific Officer (CSO) and Chairman, Dr Bruce Roser, a pioneer and distinguished scientist in this field.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STABLEVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STABLEVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More